Engflag
Advertisements

Ascoril D JUNIOR

Quick links to important sections

Ascoril D JUNIOR

Ascoril D JUNIOR_EN
Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Ascoril D JUNIOR

Quick Facts

Property Description
Active Ingredients Chlorpheniramine, Dextromethorphan, Phenylephrine
Form Oral Solution (Syrup)
Pharmacological Class Antihistamine, Antitussive, and Decongestant combination
Target Group Children (Junior formulation)
Origin Synthetic Compounds

What Type of Medicine is Ascoril D JUNIOR?

Ascoril D JUNIOR is defined as a combination medicine, manufactured as an oral solution (syrup), specifically formulated for the pediatric audience. It is a chemically synthetic preparation that integrates three distinct active components, classifying it simultaneously as an Antihistamine, an Antitussive, and a Decongestant. This multi-component formulation is used for managing the simultaneous onset of multiple upper respiratory symptoms. This triple classification ensures that the product addresses allergic reactions, coughing, and congestion concurrently.

Composition and Purpose of the Active Ingredients

The drug’s identity is built upon its three core active ingredients: Chlorpheniramine Maleate, Dextromethorphan Hydrobromide, and Phenylephrine Hydrochloride. Each compound belongs to a different pharmacological class and serves a distinct function. Chlorpheniramine is the antihistamine component, mitigating allergic manifestations like sneezing and watery eyes. Dextromethorphan is the antitussive, addressing the dry cough reflex, while Phenylephrine, an alpha-1 agonist, acts as the decongestant to relieve nasal congestion. Phenylephrine functions by narrowing blood vessels in the nasal passages. The pleasant syrup base of this oral solution is a specific differentiating factor, designed to facilitate administration to the target age group.

The General Benefit of a Combination Formula

The overarching general purpose of Ascoril D JUNIOR is to provide temporary relief from the uncomfortable, co-occurring symptoms of the common cold and seasonal allergies. By combining agents that calm the cough reflex, reduce nasal swelling via vasoconstriction, and block histamine action, the formulation offers an integrated method of symptom management. This design streamlines care for children experiencing the complex symptom cluster of runny nose, dry cough, and nasal stuffiness with a single oral formulation, which is a key positioning element for the Junior formulation.

Regulatory References

  1. Phenylephrine: MedlinePlus Drug Information
  2. DailyMed: Chlorpheniramine, Dextromethorphan, and Phenylephrine Label
Advertisements

What side effects are possible with Ascoril D JUNIOR?

Possible Side Effects and Safety Information

The safety profile of this combination medicine is officially characterized by effects related to its three components: the antihistamine (Chlorpheniramine), the cough suppressant (Dextromethorphan), and the decongestant (Phenylephrine). Adverse reactions are classified and reported according to their frequency and the body system affected, consistent with government regulatory documentation.

Classification Examples of Documented Effects
Very Common Sedation, Somnolence (Drowsiness)
Common Dizziness, Headache, Dry Mouth, Disturbance in attention, Nausea

System-Organ Classes and Serious Reactions

Adverse effects are documented across several body systems, notably Nervous System Disorders (e.g., excitation, tremor) and Gastrointestinal Disorders (e.g., vomiting). The label includes warnings regarding rare but serious adverse reactions. The use of this product, particularly when combined with Monoamine Oxidase Inhibitors (MAOIs), carries a documented risk of Serotonin Syndrome (Dextromethorphan component) and Hypertensive Crisis (Phenylephrine component), which are critical safety constraints.

Population-Specific Safety Considerations

The regulatory profile notes that specific populations may experience different safety patterns. Children may exhibit paradoxical effects such as agitation or excitability rather than drowsiness. Older adults are considered more susceptible to adverse effects, including neurological anticholinergic effects like confusion. Additionally, caution is officially documented for patients with underlying conditions, including severe hypertension and serious heart disease, due to the cardiovascular effects of the decongestant component. These conditions represent important limitations on use defined in the official prescribing information.

Advertisements

Overdose and Emergency Response

The official regulatory documentation for the overdose of this combination medicine outlines severe manifestations affecting multiple body systems. Overexposure may present with signs of CNS excitation, including hallucinations, tremors, restlessness, and a flushed face, or severe CNS depression progressing to unsteadiness and ultimately coma. Cardiovascular effects documented include palpitation and hypertension, which can precede circulatory collapse in severe cases. Life-threatening outcomes officially described include convulsions, respiratory depression, and cardiac arrhythmia.

When to Seek Urgent Medical Help

Government labeling mandates that emergency medical attention must be sought immediately if an overdose is suspected. Urgent medical services should be contacted for specific severe signs, including if the affected individual is unresponsive, has a seizure, or experiences trouble breathing. Prompt medical attention is critical for adults even if no initial symptoms are noticed.

Management involves supportive measures, such as gastric evacuation and the use of activated charcoal, and continuous monitoring of cardiovascular status and vital signs. Population-specific considerations note that small children are more prone to excitation and fever, while the elderly are more likely to exhibit severe adverse reactions.

Advertisements

Therapeutic Uses of Ascoril D JUNIOR

What Ascoril D JUNIOR Treats: Main Uses and Benefits

The Junior formulation is commonly used for managing symptoms associated with conditions where a complex cluster of upper respiratory discomfort is present, such as the common cold and acute episodes of seasonal allergies. It provides targeted, short-term assistance for symptoms that lead to temporary functional strain or discomfort in children.

This combination is intended for contexts where short-term symptomatic assistance is needed. The medication is applied in situations involving three key symptom domains: dry cough, nasal congestion, and allergy-related manifestations.

The medication is used to provide supportive relief when symptoms intensify and become disruptive. It addresses the common scenario where nasal blockage, sneezing, runny nose, and an irritating, dry cough occur together. The combination provides support that may help ease the overall symptom load associated with these multiple, co-occurring signs. The medication is applied when pronounced manifestations create noticeable interference with a child’s daily stability and comfort. This action may contribute to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Cough, Congestion, and Allergy Symptoms

Symptom Domain Targeted Manifestations Patient Benefit
Cough Irritating, dry, non-productive cough Supports rest and reduces nocturnal disruption
Congestion Nasal blockage, sinus stuffiness Assists with maintaining stable breathing
Allergy Sneezing, runny nose, watery eyes Contributes to easing overall symptom load

Regulatory References

  1. U.S. National Library of Medicine (DailyMed)
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

This section outlines the population eligibility and restrictions for Ascoril D JUNIOR, as documented in governmental regulatory sources.

Eligibility Scope Official Regulatory Status
Populations for whom use is allowed Children above the minimum age restriction for temporary symptomatic relief.
Populations for whom use is not recommended Children under 2 years of age. Pregnant or breastfeeding women.
Absolute Contraindications Hypersensitivity to active ingredients; use with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI).
Comorbidity Contraindications Severe Hypertension, Severe Coronary Artery Disease, Narrow-Angle Glaucoma, Urinary Retention, and Acute Asthma Attack.
Conditional Use Restrictions Use requires caution in patients with hepatic impairment, renal impairment, diabetes mellitus, hyperthyroidism, or prostatic hypertrophy.

Resulting Eligibility Structure

Official regulatory documents strictly define eligibility based on two factors: absolute prohibition and conditional restriction. The product is contraindicated across all age groups if the patient is taking an MAOI or has severe cardiovascular disease. Use is not recommended for the youngest pediatric cohort, specifically children under 2 years of age, due to established regulatory advisories. Conditional eligibility requires caution in patients with existing organ impairment (liver or kidney disease) and certain metabolic disorders, such as diabetes.

Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section summarizes clinically significant and officially documented interactions concerning Ascoril D JUNIOR, which contains Chlorpheniramine, Dextromethorphan, and Phenylephrine. This information is based on governmental regulatory documents.

Contraindicated Combinations

The co-administration of this product is strictly forbidden with Monoamine Oxidase Inhibitors (MAOIs), including Isocarboxazid, Phenelzine, Selegiline, and Tranylcypromine. The use of this product is also contraindicated within 14 days of stopping MAOI therapy due to the risk of hypertensive crisis and Serotonin Syndrome.

Clinically Significant Pharmacodynamic Interactions

Interacting Substance Category Rationale/Effect Components Involved
Central Nervous System (CNS) Depressants (e.g., Sedatives, Opioids, other Antihistamines) Enhanced additive CNS depressant effects, leading to increased drowsiness. Chlorpheniramine, Dextromethorphan
Sympathomimetic Agents (e.g., other Decongestants, Appetite Suppressants) Increased risk of cardiovascular effects, including elevated blood pressure. Phenylephrine
Antihypertensives and Beta-blockers Potential reduction in the blood pressure lowering effect of these medicines. Phenylephrine

Pharmacokinetic Interactions

CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine, Quinidine) may interfere with the metabolism of Dextromethorphan, leading to increased exposure and higher plasma concentrations of the drug component.

Advertisements

Mechanism of Action

Ascoril D JUNIOR is a combination medication that acts on distinct mechanistic domains to influence distinct biological pathways. It contains three active components: Chlorpheniramine, Phenylephrine, and Dextromethorphan.

Histamine Receptor Modulation

This domain involves the action of Chlorpheniramine, which is an H1-histamine receptor antagonist. It acts by blocking the engagement of histamine, an endogenous mediator released during specific biological events, at its target receptors. This inhibition of the histamine pathway reduces the functional activity of histamine, resulting in altered pathway signaling.

Central Cough Reflex Suppression

This block covers the action of Dextromethorphan, which engages mechanisms in the central nervous system. It acts directly on the cough center in the medulla oblongata, modifying the signaling sequences that initiate the cough reflex. By elevating the central threshold for cough stimulus, it results in modification of the reflex firing rate.

Alpha-Adrenergic Receptor Agonism

This mechanism involves Phenylephrine, which acts within domains associated with alpha-adrenergic receptor-mediated signaling. This compound initiates a cascade that causes vasoconstriction (narrowing of blood vessels) in the nasal passage. This vasoconstriction reduces the volume of the nasal mucosa, resulting in altered conductance in upper respiratory pathways.

Advertisements

Dosage and Administration Information

How to Use Ascoril D JUNIOR: Administration Guidelines

The usage of Ascoril D JUNIOR, an oral solution combining Chlorpheniramine, Dextromethorphan, and Phenylephrine, follows established guidelines that prioritize accurate dosing for the pediatric population. The drug is administered exclusively via the oral route as a liquid solution, and its application is intended strictly for short-term use during acute symptomatic episodes.

Dosing and Frequency Patterns

The dosage volume is determined by the child’s age, and administration follows a fixed time-interval schedule. The maximum total dose administered in a 24-hour period must not be exceeded.

Age Range Standard Dose Volume Typical Frequency Pattern
Children 6 to under 12 years 2.5 mL Every 4 to 6 hours
Children 2 to under 6 years 1.25 mL Every 4 to 6 hours

For children under 2 years of age, use is generally not recommended unless specifically directed by a healthcare professional.

Administration Requirements

To ensure dosage accuracy, the solution must be measured using a calibrated measuring device. The bottle should be shaken well immediately before each dose is measured and administered. The medicine may be taken with or without food, as its administration is not dependent on mealtime. If a dose is missed, it should be taken when remembered, unless it is close to the next scheduled administration; in this case, the missed dose is skipped, and the regular schedule is resumed, with a double dose never being administered.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ascoril D JUNIOR

Evidence for use in Dry Cough Associated with Cold or Allergies

Research on the combination of ingredients in Ascoril D JUNIOR (Dextromethorphan, Chlorpheniramine, and Phenylephrine) was studied for how symptoms change over time during acute respiratory illnesses. Researchers conducted short-term Randomized Controlled Trials (RCTs) and open-label studies where individuals, including children, was observed in research exploring short-term symptom changes related to symptoms of dry cough. The evidence contributes to understanding symptom patterns during conditions characterized by fluctuating or episodic manifestations.

Comparing Ascoril D JUNIOR to Other Treatments or Placebo

Some studies research examined how the combination of ingredients was evaluated in trials that included a comparator, such as an inactive treatment (placebo) or another type of over-the-counter cough and cold medication. Data show patterns related to symptom evolution across these different groups. This comparative evidence, which provides context on study designs, generally consists of trials where sample sizes were modest, meaning the results apply only to the populations studied.

Long-Term Studies and Follow-up Duration

The available evidence primarily focuses on outcomes describing episodic or acute changes because studies often focus on episodic or acute changes typical of short-lived conditions. Therefore, long-term effects are not fully established, and long-term outcomes are not well characterized in the current research. Follow-up durations were limited, which means that there is limited information for long-term outcomes.

Evidence in Pediatric and Other Special Populations

Since Ascoril D JUNIOR is manufactured as a formulation for children, the evidence relies on studies that included pediatric populations. However, data for certain groups remain insufficient. Research provides context, but it research does not determine whether an individual who falls outside of the typical study criteria will respond similarly.

What is Still Uncertain About Ascoril D JUNIOR

A number of aspects related to the research structure remain uncertain or unstudied. Comparative evidence is lacking for some alternative treatments, and subgroup findings are uncertain. Overall, the available evidence studies contribute to understanding symptom patterns, but research provides context and not individual predictions for all possible patient scenarios.

Key Studies & References

  1. Recommendations for the Use of OTC Cough and Cold Medications in Children (Systematic Review Context)
  2. Chlorpheniramine, Dextromethorphan, and Phenylephrine: Pediatric Medication (General Information and Contextual Safety)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ascoril D JUNIOR (FAQ)

Q: What is the main purpose of Ascoril D JUNIOR?

According to official product information, the medicine is used for the temporary relief of common symptoms associated with a cold or allergies. These symptoms can include cough, throat irritation, sneezing, watery eyes, and a runny or stuffy nose. The combination of active ingredients targets these distinct symptoms simultaneously.

Q: Is Ascoril D JUNIOR for wet cough or dry cough?

This formulation is officially indicated for the treatment of dry cough due to the inclusion of a cough suppressant component called Dextromethorphan. It is generally not intended for coughs that occur with a lot of phlegm or mucus.

Q: Is it normal to feel sleepy after taking Ascoril D JUNIOR?

Yes, regulatory documents list drowsiness (somnolence) and sedation as common adverse effects associated with the use of this medicine. The official warnings state that users should be cautious because this effect can be marked, particularly when driving or operating machinery.

Q: Do I need a prescription from a doctor to get Ascoril D JUNIOR?

The combination of active ingredients in this formulation is typically available as an over-the-counter (OTC) drug for temporary symptom relief. This indicates that it is commonly available without a prescription, though availability may vary by region.

Q: Is there a risk of dependency or addiction with Ascoril D JUNIOR?

Official information generally describes the components as not habit-forming or addictive when used as directed. However, regulatory bodies have issued warnings regarding the potential for misuse or abuse, particularly with the cough suppressant component, Dextromethorphan.

Q: Are there any specific foods or drinks that should be avoided when using this medicine?

Official warnings advise users to avoid or limit alcoholic beverages while using this medicine. This is due to the potential for increased central nervous system side effects, such as heightened drowsiness.

Q: Does Ascoril D JUNIOR treat allergies as well as cough?

Yes, the product is indicated to temporarily relieve symptoms due to the common cold and allergic rhinitis (e.g., hay fever). This effect is provided by the antihistamine component, Chlorpheniramine, which helps reduce symptoms like sneezing and watery eyes.

Q: Is it safe to drive or operate machinery while using Ascoril D JUNIOR?

Official warnings state that the medicine may cause marked drowsiness or dizziness, and users are cautioned about driving or operating machinery. This caution is advised due to the potential effect on alertness.

Q: Can Ascoril D JUNIOR be used for a cough related to asthma?

Official warnings state that the medicine should generally not be used for a cough due to asthma attacks or specific breathing problems like emphysema or chronic bronchitis. The medication is not intended to manage these conditions.

Q: Can Ascoril D JUNIOR cause stomach upset or nausea?

Official regulatory documents list nausea and stomach pain among the commonly reported side effects. This indicates that gastrointestinal discomfort is a documented possibility with this medication.

Q: What is the maximum number of days a person is typically recommended to use Ascoril D JUNIOR?

The medication is intended strictly for short-term use during acute episodes of illness. Official guidance often includes a warning to stop use if symptoms persist for more than seven days, as the product is intended for short-term use.

Q: Is Ascoril D JUNIOR a sedative?

While the drug is not classified solely as a sedative, it contains the antihistamine Chlorpheniramine, which is known to cause marked drowsiness and sedation. The label warns that taking other sedatives or tranquilizers may increase this effect.

Q: What should be done if someone accidentally takes too much Ascoril D JUNIOR?

The official label describes symptoms of a potential overdose, which can include agitation, confusion, hallucinations, and seizures. Official guidance for potential overdose situations advises seeking immediate medical attention.

Q: What is the difference between Ascoril D JUNIOR and regular Ascoril?

The primary difference lies in the active ingredients and their intended effect. Ascoril D JUNIOR is a combination of a cough suppressant, decongestant, and antihistamine. Other 'Ascoril' formulations often contain an expectorant (like Guaifenesin), which is intended to help thin and clear mucus.

Q: Why do some people say this medicine makes them feel dizzy?

Dizziness is officially listed as a common adverse effect associated with the use of the medicine. This is a known result of the medicine's effect on the central nervous system.

Q: Can Ascoril D JUNIOR be used to treat a sore throat?

The product is indicated for the temporary relief of throat irritation due to a cold or allergy. The indication covers temporary relief of throat irritation associated with a cold or allergy.

Q: Are there any known interactions with herbal supplements?

Official label warnings advise users to inform a healthcare provider of any herbal preparations being taken, as potential interactions with active components may increase the risk of side effects.

Q: What are the signs of a serious allergic reaction to Ascoril D JUNIOR?

Signs of a serious allergic reaction listed in official documents include hives, difficult breathing, or swelling of the face, lips, tongue, or throat. Official safety information notes that these symptoms are characteristic of a serious allergic reaction for which emergency medical attention is advised.

Q: Does this medicine contain an expectorant?

No. The active ingredients in the Ascoril D JUNIOR formulation are Chlorpheniramine, Dextromethorphan, and Phenylephrine. This combination acts to suppress cough, relieve congestion, and reduce allergy symptoms, and does not include an expectorant component such as Guaifenesin.

Q: What is the general difference in how multi-ingredient cough syrups work compared to single-ingredient ones?

Multi-ingredient syrups, like this one, contain several active components that act on different body systems (e.g., anti-allergy, cough suppression, decongestion) to target multiple symptoms at once. Single-ingredient syrups are designed to target only one symptom.

Q: Does Ascoril D JUNIOR work on post-nasal drip related cough?

The product contains a decongestant (Phenylephrine) and an antihistamine (Chlorpheniramine) which can help reduce the symptoms of nasal congestion and runny nose. Since these factors are commonly associated with a cough due to post-nasal drip, the components may address the nasal and allergic symptoms that contribute to this type of cough.

Q: How does the medicine affect sleep patterns, if at all?

One of the drug's components is known to cause drowsiness and sedation, which can affect sleep-wake cycles. Conversely, the official label also lists insomnia (difficulty sleeping) as a possible nervous system side effect for some people.

Q: Is Ascoril D JUNIOR a narcotic?

No, the components of this product are generally not classified as controlled substances (narcotics) by regulatory bodies in the same manner as opioid-based pain medications.

Q: Is it appropriate for use in infants under one year old?

Official guidance from regulatory bodies advises that cough and cold medications should generally not be used in children under two years of age. Official guidance advises that use in infants under two years of age is generally discouraged and requires specific medical supervision.

Q: What kind of cough is it not intended to treat?

The medicine is generally not intended for a cough that occurs with too much phlegm (mucus). Furthermore, official warnings state it should not be used for a cough due to pre-existing breathing problems like asthma or emphysema.

Q: Is the use of this medicine described as short-term or long-term?

Official prescribing information describes the use of this product strictly for short-term use. Patients are advised to discontinue use if symptoms do not improve or persist beyond a short duration, such as seven days.

Q: Are there studies on the use of Ascoril D JUNIOR in the elderly?

Official documents note that older adults are considered more susceptible to adverse effects (such as confusion or dizziness) from these components, and caution is advised for this population. The product is primarily marketed for pediatric use.

Q: Why is it called 'JUNIOR'—is it only for children?

The 'JUNIOR' designation indicates that the product is formulated and labeled with specific lower doses tailored for pediatric populations (children under 12). The product is focused on children, and adults are generally advised to use formulations with concentrations appropriate for adult dosing.

Q: Can Ascoril D JUNIOR be taken by adults, or just children?

The product is labeled primarily for use in children aged 2 to under 12 years, with the dosage specifically measured for this age range. The product is labeled primarily for use in children aged 2 to under 12 years, and adult cough-and-cold formulations contain concentrations generally appropriate for adult use.

Q: What is the recommended age group for Ascoril D JUNIOR?

Based on official dosing and labeling information, the medicine is intended for use in children aged 2 to under 12 years. Use in children under two years of age is generally discouraged without specific direction.

Q: What kinds of medical conditions make using Ascoril D JUNIOR potentially inappropriate?

Official warnings and contraindications advise caution or non-use in patients with conditions such as high blood pressure, heart disease, thyroid disease, diabetes, glaucoma, urinary retention, or certain breathing problems. The decongestant and antihistamine components can be risky for these conditions.

Q: Is Ascoril D JUNIOR suitable for individuals with high blood pressure?

Official warnings state that the medicine should not be used by individuals with high blood pressure (hypertension) or other serious heart-related disorders. This is a critical safety constraint related to the decongestant component, Phenylephrine.

Q: Can the medicine be used by someone who is pregnant or breastfeeding (as described in official sources)?

Official warnings advise against the use of this product during pregnancy or while breastfeeding. One of the components, Chlorpheniramine, is described as passing into breast milk.

Q: Does Ascoril D JUNIOR contain alcohol or sugar?

Liquid preparations of this type of product may contain sugar and/or alcohol as inactive ingredients. The official warning indicates that patients with conditions like diabetes or alcohol dependence should be aware of the excipients in the formulation.

Q: What type of research has been conducted on the components of Ascoril D JUNIOR?

The official evidence relies primarily on short-term Randomized Controlled Trials (RCTs). These studies examine how the components affect symptoms of acute respiratory illnesses over a limited duration to establish an understanding of short-term symptom patterns.

Q: Can Ascoril D JUNIOR be taken with other cold and flu remedies?

Official warnings advise against taking other cough-and-cold medication that might contain the same or similar ingredients (e.g., other antihistamines or decongestants). Combining these products increases the risk of exceeding safe doses and experiencing serious side effects.

Advertisements

How should Ascoril D JUNIOR be stored and disposed of?

Storage and Environmental Requirements

Ascoril D JUNIOR Syrup must be stored in alignment with official regulatory requirements to maintain its stability. The medicine must be kept at room temperature or below 25 C in a cool and dry place. It is mandatory to protect the syrup from light and moisture, as exposure to these elements can compromise the product.

Packaging and Child Safety

The medicine must be kept in its original container and the cap must be tightly closed when not in use. As a non-negotiable safety rule for pediatric formulations, the syrup must be stored out of the reach and sight of children and pets at all times.

Disposal Instructions

Expired or unused Ascoril D JUNIOR must be disposed of according to the instructions on the package label and local regulatory guidelines. Do not dispose of the syrup by pouring it down the sink or toilet, as this may impact wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ascoril D JUNIOR found in:

A-Z Index: